Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
12.46
-0.06 (-0.48%)
Jul 1, 2026, 10:54 AM EDT - Market open
Polyrizon Employees
As of December 31, 2025, Polyrizon had 4 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 2 or -33.33% compared to the previous year.
Employees
4
Change (1Y)
-2
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$833,750
Market Cap
23.32M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | -2 | -33.33% | 2 | 2 |
| Dec 31, 2024 | 6 | - | - | 2 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Longeveron | 38 |
| Palatin Technologies | 29 |
| Lipocine | 14 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
| VYNE Therapeutics | 10 |
| Allarity Therapeutics | 8 |
PLRZ News
- 2 days ago - Polyrizon receives central IRB approval for Nasarix - TheFly
- 2 days ago - Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial - GlobeNewsWire
- 14 days ago - Polyrizon gets patent for Trap & Target mucoadhesive polymer technology platform - TheFly
- 14 days ago - Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform - GlobeNewsWire
- 16 days ago - Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway - GlobeNewsWire
- 21 days ago - Polyrizon receives notice of European patent publication - TheFly
- 21 days ago - Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology - GlobeNewsWire
- 23 days ago - Polyrizon signs agreements with two additional clinical sites for Nasarix study - TheFly